<!doctype html>
<html lang="en">
  <head>
    <!-- Title and description ================================================== -->
    
              <meta name="csrf-param" content="authenticity_token">
              <meta name="csrf-token" content="DZS4T61YhbV6DkyBu6exwZ0daCYVjr/j0bxpx8Vt+UOxXiQNha6A5o5PDQ+CF1UggBfXMW0gEZGUgRYp2hIo0g==">
            
    <title>
      
        Moby | Become a smarter investor in just 5 minutes
      
    </title>
    <meta charset="utf-8" />
    <meta content="IE=edge,chrome=1" http-equiv="X-UA-Compatible">
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
    
      <meta name="description" content="We send you daily investing strategies, stock research, and crypto analysis that&#39;s fun to read and easy to digest. Join today for free and start making smarter investing decisions." />
    

    <!-- Helpers ================================================== -->
    
    
      <link href="https://kajabi-storefronts-production.kajabi-cdn.com/kajabi-storefronts-production/themes/2148837788/settings_images/cT6NmsumSriMG1LbzqFR_Untitled_design_17.png?v=2" rel="shortcut icon" />
    
    <link rel="canonical" href="2151894392.html" />

    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.5.0/css/all.css" integrity="sha384-B4dIYHKNBt8Bc12p+WXckhzcICo0wtJAoU8YZTY5qE0Id1GSseTk6S+L3BlXeVIU" crossorigin="anonymous">


    <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.1.3/css/bootstrap.min.css" integrity="sha384-MCw98/SFnGE8fJT3GXwEOngsV7Zt27NXFoaoApmYm81iuXoPkFOJwJ8ERdknLPMO" crossorigin="anonymous">
    
      <link href="https://fonts.googleapis.com/css?family=Poppins:400,700,400italic,700italic" rel="stylesheet" type="text/css">
    
    <link rel="stylesheet" media="screen" href="https://kajabi-app-assets.kajabi-cdn.com/assets/core-8cc7151051efbc8322c251aae2b556b928bcd0ebfc79f909c1f847eed9932b7f.css" />
    <link rel="stylesheet" media="screen" href="https://kajabi-storefronts-production.kajabi-cdn.com/kajabi-storefronts-production/themes/2148837788/assets/styles.css?1634851986331554" />

    <!-- Header hook ================================================== -->
    <script type="text/javascript">
  var Kajabi = Kajabi || {};
</script>
<script type="text/javascript">
  Kajabi.currentSiteUser = {
    "id" : "2160609026",
    "type" : "Member"
  };
</script>
<script type="text/javascript">
  Kajabi.theme = {
    activeThemeName: "Production Live",
    previewThemeId: null,
    editor: false
  };
</script>
<script>
(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)
},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,'script','//www.google-analytics.com/analytics.js','ga');

ga('create', 'UA-199580424-1', 'auto', {"userId":2202749271});
ga('send', 'pageview');
</script>
<style type="text/css">
  #editor-overlay {
    display: none;
    border-color: #2E91FC;
    position: absolute;
    background-color: rgba(46,145,252,0.05);
    border-style: dashed;
    border-width: 3px;
    border-radius: 3px;
    pointer-events: none;
    cursor: pointer;
    z-index: 10000000000;
  }
  .editor-overlay-button {
    color: white;
    background: #2E91FC;
    border-radius: 2px;
    font-size: 13px;
    margin-left: -24px;
    margin-top: -12px;
    padding: 3px 10px;
    text-transform:uppercase;
    font-weight:bold;
    letter-spacing:1.5px;

    left: 50%;
    top: 50%;
    position: absolute;
  }
</style>
<script>
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version='2.0';n.agent='plkajabi';n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
                                                                      document,'script','https://connect.facebook.net/en_US/fbevents.js');

fbq('init', '664252340905038', {"ct":null,"country":null,"em":"ilya.ek@gmail.com","fn":"Ilya","ln":"Kiselev","pn":null,"zp":null});
fbq('track', "PageView");</script>
<noscript><img height="1" width="1" style="display:none"
src="https://www.facebook.com/tr?id=664252340905038&ev=PageView&noscript=1"
/></noscript>
<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-5SBLJRW');</script>
<!-- End Google Tag Manager --><meta name='site_locale' content='en'>
  </head>
  <body class="d-flex flex-fill">

    <div class="main-sidebar col flex-fill">
  <div id="section-mini_dashboard" data-section-id="mini_dashboard">














<div class="mini-dashboard">
  <a href="../../../../premium-investing-research.1.html" class="mini-dashboard-back" kjb-settings-id="sections_mini_dashboard_settings_dashboard">
    <i class="fas fa-chevron-left"></i>
    Dashboard
  </a>
  <h1 class="mini-dashboard-title">Premium Investing Research</h1>
  <div class="media">
    <div class="mr align-self-center">
      <div class="avatar avatar-sm avatar-light avatar-1">
        <img class="avatar-img" src="https://www.gravatar.com/avatar/df42ea502a25d65db01cfd5e62d26643?s=42&d=https://s3.amazonaws.com/kajabi-storefronts-production/static_assets/default_avatar.jpg"/>
      </div>
    </div>
    <div class="media-body">
      <h5 class="mini-dashboard-user">Ilya Kiselev</h5>
      <div class="mini-dashboard-completion" kjb-settings-id="sections_mini_dashboard_settings_complete">1% Complete</div>
    </div>
  </div>
</div>

</div>
  <div id="section-product_outline" data-section-id="product_outline">

<div class="product-outline">
  
    
      <h3 class="product-outline-category"><a href="../../2148695518.html">Investing Strategies</a></h3>
      
      
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148695519.1.html">Information Technology</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148695520.1.html">Consumer Discretionary</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148721378.1.html">Industrials</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148721389.1.html">Financials</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148721380.1.html">Health Care</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148721417.1.html">Communication Services</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148721435.1.html">Energy</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148721471.html">Real Estate</a></h3>
            
          
        
          
            <h3 class="product-outline-subcategory"><a href="../../2148721438.html">Materials</a></h3>
            
          
        
      
    
  
    
      <h3 class="product-outline-category"><a href="../../2148737584.1.html">Crypto</a></h3>
      
      
    
  
    
      <h3 class="product-outline-category"><a href="../../2148721319.1.html">Market & Industry Analysis</a></h3>
      
      
    
  
    
      <h3 class="product-outline-category"><a href="../../2148721346.1.html">Rankings and Lists</a></h3>
      
      
    
  
    
      <h3 class="product-outline-category"><a href="../../2148721443.1.html">Hedge Fund Holdings</a></h3>
      
      
    
  
    
      <h3 class="product-outline-category"><a href="../../2148721457.1.html">Portfolio Strategy</a></h3>
      
      
    
  
</div>
</div>
</div>
<div class="main-content col flex-fill">
  





<div class="responsive-toggle">
  <div class="media">
    <div class="align-self-center"><i class="responsive-toggle-trigger fas fa-bars"></i></div>
    <div class="align-self-center media-body">
      
        <form action="https://www.moby.co/products/premium-investing-research/search" method="get" role="search">
          <div class="input-group search" kjb-settings-id="show_search">
            <div class="input-group-prepend">
              <div class="input-group-text search-icon"><i class="fa fa-search"></i></div>
            </div>
            <input class="form-control search-input" type="search" name="q" placeholder="Search for something..." kjb-settings-id="search_text">
          </div>
        </form>
      
    </div>
  </div>
</div>

  






  <form action="https://www.moby.co/products/premium-investing-research/search" method="get" role="search">
    <div class="input-group search post-page" kjb-settings-id="show_search">
      <div class="input-group-prepend">
        <div class="input-group-text search-icon"><i class="fa fa-search"></i></div>
      </div>
      <input class="form-control search-input" type="search" name="q" placeholder="Search for something..." kjb-settings-id="search_text">
    </div>
  </form>


  





  <div id="section-post_actions" data-section-id="post_actions">















<div class="post-actions" kjb-settings-id="sections_post_actions_settings_downloads">
  <div class="media align-items-center">
    <div class="post-actions-pagination">
      
        <a href="2151894318.html">
          <i class="fas fa-angle-left"></i>
        </a>
      
    </div>
    <div class="media-body">
      <div class="post-actions-container">
        <div class="media align-items-center">
          <div class="media-body">
            
            

          </div>
          <div>
            <a href="2151894392.html#" data-favorite-toggle="true" data-favorited="false" data-favorite-token="BAh7CEkiCGdpZAY6BkVUSSIpZ2lkOi8va2FqYWJpLXBvcnRhbHMvUG9zdC8yMTUxODk0MzkyBjsAVEkiDHB1cnBvc2UGOwBUSSIOZmF2b3JpdGVzBjsAVEkiD2V4cGlyZXNfYXQGOwBUSSIdMjAyMS0xMS0yM1QxNjo1NDoxOC43ODBaBjsAVA==--4367d75a89a9a01b68a26ecdd1f8d44be79fac91" class="post-actions-favorite ">
              <i class="far fa-star"></i>
            </a>
          </div>
          <div>
            <a href="2151894392.html#" data-complete-text="Mark As Read" data-incomplete-text="Read" data-post-completion-toggle="false" data-token="eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJhY3Rvcl90eXBlIjoiTWVtYmVyIiwiYWN0b3JfaWQiOjIxNjA2MDkwMjYsInByb2R1Y3RfaWQiOjIxNDc2MzM1MzcsInBvc3RfaWQiOjIxNTE4OTQzOTJ9.1KFR4cwtTV_JbMPcCRbIwnGEeuIF8v_He3tAqfmKR_Y" class="btn post-actions-complete">
              
                Mark As Read
              
            </a>
          </div>
        </div>
      </div>
    </div>
    <div class="post-actions-pagination">
      
        <a href="2151894411.html">
          <i class="fas fa-angle-right"></i>
        </a>
      
    </div>
  </div>
</div>

</div>
  <div class="post-body">
  <div class="main-content-container">
    

    <h1 class="post-body-title">Eli Lilly: Slowing Down Alzheimer's?</h1>
    <div data-mobiledoc="{&quot;version&quot;:&quot;0.3.2&quot;,&quot;atoms&quot;:[[&quot;soft-return&quot;,&quot;&quot;,{}],[&quot;soft-return&quot;,&quot;&quot;,{}]],&quot;cards&quot;:[],&quot;markups&quot;:[[&quot;strong&quot;]],&quot;sections&quot;:[[1,&quot;p&quot;,[[0,[0],1,&quot;Stock: &quot;],[0,[],0,&quot;Eli Lilly (LLY) | &quot;],[0,[0],1,&quot;Rating: &quot;],[0,[],0,&quot;Overweight&quot;],[1,[],0,0],[0,[0],1,&quot;Price Target: &quot;],[0,[],0,&quot;$200&quot;],[1,[],0,1],[0,[0],1,&quot;Target Date: &quot;],[0,[],0,&quot;12/2021&quot;]]],[1,&quot;p&quot;,[[0,[0],1,&quot;Headline:&quot;]]],[1,&quot;p&quot;,[[0,[],0,&quot;Shares of the biopharmaceutical giant Eli Lilly (LLY) rose over 10% in early trading this morning! The reason why? Investors are responding to the new promising published data on the early Alzheimer" s="" drug="" donanemab="" in="" early="" trials="" showed="" a="" positive="" effect="" on="" slowing="" down="" the="" cognitive="" decline="" effects="" of="" alzheimer="" while="" only="" phase="" 2="" this="" could="" be="" major="" new="" treatment="" made="" available="" for="" lly="" should="" it="" ultimately="" approved="" 1="" p="" 0="" details:="" so="" what="" actually="" happened="" and="" did="" data="" say="" today="" announced="" their="" met="" primary="" endpoint="" change="" from="" baseline="" to="" 76="" weeks="" integrated="" disease="" rating="" scale="" -="" by="" up="" 32="" relative="" placebo="" used="" matches="" initial="" shown="" better="" yet="" safety="" profile="" was="" also="" consistent="" with="" which="" is="" very="" encouraging="" trial="" done="" patient="" group="" 272="" patients="" showing="" stages="" we="" do="" not="" have="" full="" results="" but="" they="" will="" posted="" future="" medical="" meeting="" next="" steps:="" discuss="" regulators="" assess="" steps="" if="" these="" conversations="" go="" well="" may="" able="" file="" fda="" approval="" however="" undergone="" study="" different="" types="" earlier="" summer="" completed="" several="" years="" even="" first="" batch="" second="" would="" still="" away="" conclusion:="" conclusive="" promising="" thus="" far="" take="" get="" fully="" all="" at="" timeline="" approvals="" like="" are="" uncommon="" news="" long="" stock="" investing="" cautiously="" turn="" worse="" additionally="" midst="" overall="" portfolio="" medicine="" represents="" piece="" business="" accepted="" rolled="" out="" nationally="" implications="" massive="" interim="" looking="" rest="" pipeline="" until="" such="" an="" event="" happen="" term="" upcoming="" testing="" see="" other="" coming="" soon="" that="" as="" e="" g="" tirzepatide="" diabetes="" continue="" company="" treatments="" forward="" basis="" therefore="" overweight="" over="" anticipate="" price="" appreciate="" risks="" watching="" terms="" short="" spikes="" financial="" misses="" disappointments="" any="" pricing="" complications="">
<div>
<p><em><span style="color: #bacfe7;"><strong>Published on December 25, 2020</strong></span></em></p>
<p><strong>Stock: </strong>Eli Lilly (LLY)</p>
<p><strong>Rating: </strong>Overweight</p>
<p><strong>Price Target: </strong>$200</p>
<p><strong>Target Date: </strong>12/2021</p>
<p>&nbsp;</p>
<hr />
<h2>&nbsp;</h2>
<h2><strong>Headline:</strong></h2>
<p>Shares of the biopharmaceutical giant Eli Lilly (LLY) rose over 10% in early trading this morning! The reason why? Investors are responding to the new promising published data on the early Alzheimer's drug, Donanemab. In early trials, Donanemab showed a positive effect on slowing down the cognitive decline effects of Alzheimer's! While only in phase 2, this could be a major new treatment made available for LLY should it ultimately be approved!</p>
<h2>&nbsp;</h2>
<h2><strong>Details:</strong></h2>
<p>So what actually happened and what did the data say? Today LLY announced their drug met the primary endpoint of change from the baseline to 76 weeks in the integrated Alzheimer's disease rating scale - slowing the decline by up to 32% relative to the placebo used in the trials! This data, matches the initial data shown in phase 1. Better yet, the safety profile was also consistent with the data in phase 1 - which is very encouraging! The trial was done on a patient group of 272 patients showing the initial stages of cognitive decline. We do not have the full results yet, but they will be posted in a future medical meeting!</p>
<h2>&nbsp;</h2>
<h2><strong>Next Steps:</strong></h2>
<p>So what's next? LLY will discuss the results of this trials with regulators to assess what the next steps should be. If these conversations go well, LLY may be able to file this trial with the FDA for approval! However, they have also undergone a study with different types of Alzheimer's patients earlier this summer, which will not be completed for several years. So even if the first batch was to be approved, the second would still be years away!</p>
<h2>&nbsp;</h2>
<h2><strong>Conclusion:</strong></h2>
<p>While not conclusive yet, Donanemab is showing very promising results thus far. And while it may take years to get it fully approved for all patients, at scale, FDA timeline approvals like these, are not uncommon. So while do like the promising news, and are long the stock, we are still investing cautiously should the news take a turn for the worse.</p>
<p>Additionally in the midst of their overall portfolio, this medicine also represents only a piece of their overall business. Should it be approved, accepted and rolled out nationally, the implications would be massive. But in the interim, looking at the rest of their pipeline until such an event should happen, in term's of upcoming drug approvals and testing, we see other trials coming up soon that should be promising as well (e.g. Tirzepatide for Diabetes)! All in all, we have and continue to like LLY as a company and the treatments in their pipeline on a go forward basis. We therefore are overweight the stock over the long term and anticipate the price to appreciate. The risks we are watching for, in terms of short terms spikes would be, and financial misses, pipeline disappointments and any drug pricing complications.</p>
</div>
</div>
    <hr />
  </div>
</div>

  


  <div class="comments">
    <div class="main-content-container">
      
        <form novalidate="novalidate" class="new_comment" id="new_comment" action="https://www.moby.co/posts/2151894392/comments" accept-charset="UTF-8" data-remote="true" method="POST"><input name="utf8" type="hidden" value="âœ“">
          <div class="media">
            <div>
              <img class="comments-img" src="https://www.gravatar.com/avatar/df42ea502a25d65db01cfd5e62d26643?s=42&d=https://s3.amazonaws.com/kajabi-storefronts-production/static_assets/default_avatar.jpg"/>
            </div>
            <div class="media-body">
              <textarea kjb-settings-id="language_comment_placeholder" rows="5" placeholder="Say Something..." name="comment[body]" id="comment_body" class="form-control"></textarea>
              <input kjb-settings-id="language_comment_add" class="btn comments-btn" type="submit" name="commit" data-disable-with="submitting" value="Post Comment">
            </div>
          </div>
        </form>
      
      
    </div>
  </div>


</div>
<div id="section-post_completion" data-section-id="post_completion">
























<div class="post-completion" data-page="/products/premium-investing-research/categories/2148721380/posts/2151894411" data-counter="10" data-auto="false">
  <div class="post-completion-box">
    <div class="avatar avatar-md avatar-grey avatar-1">
      <img class="avatar-img" src="https://www.gravatar.com/avatar/df42ea502a25d65db01cfd5e62d26643?s=42&d=https://s3.amazonaws.com/kajabi-storefronts-production/static_assets/default_avatar.jpg"/>
    </div>
    <div class="post-completion-box-percent" kjb-settings-id="sections_post_completion_settings_complete_text">1% Complete</div>
    <h4 class="post-completion-box-message" kjb-settings-id="sections_post_completion_settings_message_text">Nice Work, Ilya</h4>
    <p class="post-completion-box-post" kjb-settings-id="sections_post_completion_settings_lesson_text">You just completed the lesson:<br />Eli Lilly: Slowing Down Alzheimer's?</p>
    
      <a href="2151894411.html" class="btn post-completion-box-btn" kjb-settings-id="sections_post_completion_settings_next_text">
        Go to Next Lesson
      </a>
    
    <a href="2151894392.html#" class="post-completion-box-cancel" kjb-settings-id="sections_post_completion_settings_cancel_text">Cancel</a>
  </div>
  
</div>


</div>

    <!-- Javascripts ================================================== -->
    <script src="https://kajabi-app-assets.kajabi-cdn.com/assets/core-0664a32a302da74190b5d9deb7357551e8d29b4a22f5c04abbef07d27402c317.js"></script>
    <script charset='ISO-8859-1' src='https://fast.wistia.com/assets/external/E-v1.js'></script>
    <script charset='ISO-8859-1' src='https://fast.wistia.com/labs/crop-fill/plugin.js'></script>
    <script src="https://kajabi-storefronts-production.kajabi-cdn.com/kajabi-storefronts-production/themes/2148837788/assets/scripts.js?1634851986331554"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.3/umd/popper.min.js" integrity="sha384-ZMP7rVo3mIykV+2+9J3UJ46jBk0WLaUAdn689aCwoqbBJiSnjAK/l8WvCWPIPm49" crossorigin="anonymous"></script>
    <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.1.3/js/bootstrap.min.js" integrity="sha384-ChfqqxuZUCnJSK3+MXmPNIyE6ZbWh2IMqE241rYiqJxyMiZ6OW/JmZQ5stwEULTy" crossorigin="anonymous"></script>
  </body>
</html>